Tralokinumab, an anti-interleukin-13 monoclonal antibody, reduces Staphylococcus aureus colonization of the skin and systemic levels of inflammatory biomarkers in atopic dermatitis patients

Interleukin (IL)-13 plays an important role in atopic dermatitis (AD) pathogenesis. Tralokinumab is a fully human monoclonal antibody that potently and specifically neutralizes IL-13. In this phase 2b study (NCT02347176), 204 adults with moderate-to-severe AD were randomized 1:1:1:1 to receive subcutaneous tralokinumab 45 mg, 150 mg, or 300 mg, or placebo, every 2 weeks for 12 weeks. Concomitant Class 3 (World Health Organization) topical corticosteroids were administered at least once daily during a 2-week run-in and as needed throughout the treatment and follow-up periods.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research